Aptus Capital Advisors LLC Grows Holdings in Ocular Therapeutix, Inc. $OCUL

Aptus Capital Advisors LLC boosted its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 1.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 346,098 shares of the biopharmaceutical company’s stock after buying an additional 6,348 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Ocular Therapeutix were worth $2,537,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in shares of Ocular Therapeutix during the fourth quarter worth about $28,000. Brooklyn Investment Group boosted its holdings in Ocular Therapeutix by 151.5% in the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 3,155 shares during the last quarter. GAMMA Investing LLC grew its stake in Ocular Therapeutix by 6,760.0% during the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 8,112 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Ocular Therapeutix by 2,045.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 8,446 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in Ocular Therapeutix during the 4th quarter worth approximately $90,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on OCUL shares. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research note on Thursday, May 29th. Needham & Company LLC increased their price objective on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Finally, Scotiabank dropped their target price on shares of Ocular Therapeutix from $22.00 to $20.00 and set a “sector outperform” rating for the company in a research report on Wednesday, August 6th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $17.20.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,219 shares of the stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the sale, the insider owned 3,499,099 shares in the company, valued at $25,123,530.82. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders have sold 29,079 shares of company stock worth $208,739. 2.30% of the stock is owned by corporate insiders.

Ocular Therapeutix Stock Performance

OCUL stock opened at $11.96 on Thursday. The stock’s 50 day simple moving average is $10.78 and its 200 day simple moving average is $8.62. Ocular Therapeutix, Inc. has a 12-month low of $5.78 and a 12-month high of $12.91. The firm has a market cap of $2.08 billion, a P/E ratio of -9.34 and a beta of 1.49. The company has a current ratio of 10.10, a quick ratio of 10.02 and a debt-to-equity ratio of 0.23.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.04). The business had revenue of $13.46 million for the quarter, compared to the consensus estimate of $13.12 million. Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. The firm’s revenue for the quarter was down 17.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.26) EPS. As a group, equities research analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.